A Phase 3 interventional study of GW685698X in Vasomotor Rhinitis and Rhinitis, Vasomotor, sponsored by GlaxoSmithKline. Completed at 59 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS was a rating of the severity of symptoms over the previous 12 hours and was performed in the morning (AM rTNSS) and evening (post meridian \[PM\] rTNSS). The daily rTNSS was the sum of two assessments. The Baseline daily rTNSS was defined as the average of the daily rTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline.
Time frame: Baseline and up to Week 4
Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)
The morning pre-dose iTNSS was the sum of the individual symptom score for rhinorrhoea, nasal congestion and postnasal drip performed immediately prior to taking the daily dose which were scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The Baseline daily iTNSS was defined as the average of the daily iTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline value.
Time frame: Baseline and up to Week 4
Number of Participants Based on Overall Evaluation of Response to Therapy
Participants were evaluated effectiveness of study medication for relieving non-allergic rhinitis symptoms over the entire treatment period. The overall evaluation of response to therapy was based on a 7-point categorical scale (1-7) where the participants rate their perception of the change or lack of change in their VMR symptoms at the end of the study. The 7 categories were: 1: significantly improved, 2: moderately improved, 3: mildly improved, 4: no change, 5: mildly worse, 6: moderately worse and 7: significantly worse. Effectiveness of study medication for relieving VMR symptoms over the entire treatment period.
Time frame: Week 4 (Day 29) or Early Withdrawal
The actual dose delivered from the product was 27.5 micrograms (µg) /actuation, which is therefore proposed as the label claim rather than 25 µg/actuation. Based on this spray content assessment, the dose examined in this study was actually 110 µg rather than the 100 µg dose indicated in the protocol.
| Milestone | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| Started | 173 | 174 |
| Completed | 168 | 165 |
| Not completed | 5 | 9 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Participant took two different treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Lost to follow-up | 1 | 2 |
The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS was a rating of the severity of symptoms over the previous 12 hours and was performed in the morning (AM rTNSS) and evening (post meridian \[PM\] rTNSS). The daily rTNSS was the sum of two assessments. The Baseline daily rTNSS was defined as the average of the daily rTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline.
| Score on a scale | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS) | -2.11 ± 0.15 | -2.01 ± 0.15 |
The morning pre-dose iTNSS was the sum of the individual symptom score for rhinorrhoea, nasal congestion and postnasal drip performed immediately prior to taking the daily dose which were scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The Baseline daily iTNSS was defined as the average of the daily iTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline value.
| Score on a scale | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS) | -1.65 ± 0.14 | -1.59 ± 0.14 |
Participants were evaluated effectiveness of study medication for relieving non-allergic rhinitis symptoms over the entire treatment period. The overall evaluation of response to therapy was based on a 7-point categorical scale (1-7) where the participants rate their perception of the change or lack of change in their VMR symptoms at the end of the study. The 7 categories were: 1: significantly improved, 2: moderately improved, 3: mildly improved, 4: no change, 5: mildly worse, 6: moderately worse and 7: significantly worse. Effectiveness of study medication for relieving VMR symptoms over the entire treatment period.
| Participants | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| Significantly Improved | 20 | 28 |
| Moderately Improved | 39 | 41 |
| Mildly Improved | 42 | 43 |
| No Change | 63 | 50 |
| Mildly Worse | 3 | 4 |
| Moderately Worse | 2 | 3 |
| Significantly Worse | 3 | 2 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from on or after the randomization date (Up to Day 34).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/173 (0%) | 0/173 (0%) | 38/173 (22%) |
| Fluticasone Furoate 110 µg QD | 0/174 (0%) | 1/174 (0.6%) | 42/174 (24.1%) |
| Event | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| Nephrotic syndromeRenal and urinary disorders | 0/173 | 1/174 |
| Event | Placebo | Fluticasone Furoate 110 µg QD |
|---|---|---|
| HeadacheNervous system disorders | 16/173 | 14/174 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 5/173 | 12/174 |
| NasopharyngitisInfections and infestations | 10/173 | 11/174 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 5/173 | 4/174 |
| Back painMusculoskeletal and connective tissue disorders | 4/173 | 1/174 |
| Upper respiratory tract infectionInfections and infestations | 4/173 | 1/174 |
| DiarrhoeaGastrointestinal disorders | 0/173 | 4/174 |
| Age, Continuous(Years) | Placebo | Fluticasone Furoate 110 µg QD | Total |
|---|---|---|---|
| Mean | 44 ± 14.72 | 43.8 ± 15.44 | 43.9 ± 15.06 |
| Sex: Female, Male(Participants) | Placebo | Fluticasone Furoate 110 µg QD | Total |
|---|---|---|---|
| Female | 108 | 124 | 232 |
| Male | 65 | 50 | 115 |
| Race (NIH/OMB)(Participants) | Placebo | Fluticasone Furoate 110 µg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 6 | 13 |
| White | 164 | 167 | 331 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jul 2005, a primary completion of Feb 2006 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 11 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate
Rhinitis, Vasomotor